Search Results
Jun 03, 2026, 18:01 ET ERA 총회: FLOW 임상시험, 세마글루타이드가 당뇨병 및 신장 질환 환자의 삶의 질 개선과 관련 있음을 보여줘
무작위 배정된 참가자 3533명 중 1767명은 세마글루타이드를, 1766명은 위약을 투여받았다. 건강 관련 삶의 질은 이동성, 자기관리, 일상 활동, 통증/불편감, 불안/우울, 전반적인 건강 인식을 포함해 건강 상태와 웰빙을 평가하는 환자 보고 척도인 EQ-5D-5L 설문지를 통해 평가됐다.치료 2년 후 건강 효용 점수(0은 사망, 1은 완전한 건강 상태)는 세마글루타이드군에서 안정적으로 유지됐으나 위약군에서는 감소했다. 추정 치료 차이 +0.021(p=0.0001)은 연간 완전한 건강 상태로 지내는 날이 약 8일 추가되는
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows
randomised participants in the FLOW trial, 1,767 received semaglutide and 1,766 received placebo. Health-related quality of life was assessed using the EQ-5D-5L questionnaire, a patient-reported measure of health status and well-being covering mobility, self-care, usual activities, pain/discomfort, anxiety/depression,
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows
randomised participants in the FLOW trial, 1,767 received semaglutide and 1,766 received placebo. Health-related quality of life was assessed using the EQ-5D-5L questionnaire, a patient-reported measure of health status and well-being covering mobility, self-care, usual activities, pain/discomfort, anxiety/depression,
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA-Kongress: Die FLOW-Studie zeigt, dass Semaglutid die Lebensqualität bei Diabetes und Nierenerkrankungen verbessert
randomisierten Teilnehmern der FLOW-Studie erhielten 1.767 Semaglutid und 1.766 Placebo. Die gesundheitsbezogene Lebensqualität wurde anhand des EQ-5D-5L-Fragebogens bewertet, einem von den Patienten selbst erstellten Maß für den Gesundheitszustand und das Wohlbefinden, das Mobilität, Selbstversorgung,
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA Congress: Semaglutida ligada a melhor qualidade de vida em diabetes e doença renal, mostra teste DE FLUXO
no estudo FLOW, 1.767 receberam semaglutida e 1.766 receberam placebo. A qualidade de vida relacionada à saúde foi avaliada usando o questionário EQ-5D-5L, uma medida relatada pelo paciente do estado de saúde e bem-estar, abrangendo mobilidade, autocuidado, atividades habituais, dor/desconforto, ansiedade/depressão
More news about: ERA Congress
Jun 03, 2026, 18:01 ET Congreso ERA: El ensayo FLOW muestra beneficios de la semaglutida
ensayo FLOW, 1.767 recibieron semaglutida y 1.766 recibieron placebo. La calidad de vida relacionada con la salud se evaluó mediante el cuestionario EQ-5D-5L, una medida autoinformada del estado de salud y el bienestar que abarca la movilidad, el autocuidado, las actividades cotidianas, el dolor/malestar,
More news about: ERA Congress
Jun 03, 2026, 18:01 ET Congrès de l'ERA : L'essai FLOW montre que le sémaglutide est associé à une meilleure qualité de vie dans le diabète et les maladies rénales
randomisés de l'étude FLOW, 1 767 ont reçu le semaglutide et 1 766 le placebo. La qualité de vie liée à la santé a été évaluée à l'aide du questionnaire EQ-5D-5L, une mesure de l'état de santé et du bien-être déclarée par le patient et portant sur la mobilité, les soins personnels, les activités habituelles,
More news about: ERA Congress
Jun 03, 2026, 18:01 ET Congreso ERA: Semaglutida vinculada a una mejor calidad de vida en la diabetes y la enfermedad renal, muestra EL ENSAYO FLOW
ensayo FLOW, 1.767 recibieron semaglutida y 1.766 recibieron placebo. La calidad de vida relacionada con la salud se evaluó mediante el cuestionario EQ-5D-5L, una medida de estado de salud y bienestar informada por el paciente que cubre la movilidad, el autocuidado, las actividades habituales, el dolor/malestar,
More news about: ERA Congress
Jun 03, 2026, 17:13 ET Bitmine Immersion Technologies (BMNR) annuncia che le sue partecipazioni in ETH raggiungono i 5,42 milioni di token e che le partecipazioni totali in criptovalute e liquidità ammontano a 11,6 miliardi di dollari
totale pari a 446 milioni di dollari. Le partecipazioni in ETH di Bitmine rappresentano il 4,49% dell'offerta di ETH (pari a 120,7 milioni di ETH).L'11 maggio 2026, Bitmine ha pubblicato l'ultimo messaggio del suo presidente (
More news about: Bitmine Immersion Technologies, Inc.
Jun 03, 2026, 15:33 ET EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA® VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM LUNGENKREBS IM FORTGESCHRITTENEN STADIUM
https://www.clinicaltrials.gov/study/NCT05740566.Rudin CM, Mountzios GS, Sun L, et al. Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small-cell lung cancer: primary analysis of Ph3 DeLLphi-304. Mündliche Präsentation auf der: ASCO-Jahrestagung;
More news about: Amgen
Jun 03, 2026, 15:16 ET LA COMMISSION EUROPÉENNE APPROUVE IMDYLLTRA® D'AMGEN POUR LE TRAITEMENT DU CANCER DU POUMON À PETITES CELLULES DE STADE ÉTENDU
https://www.clinicaltrials.gov/study/NCT05740566.Rudin CM, Mountzios GS, Sun L, et al. Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small-cell lung cancer: primary analysis of Ph3 DeLLphi-304. Présentation orale : Réunion annuelle de l'ASCO
More news about: Amgen
Jun 03, 2026, 14:25 ET EURÓPSKA KOMISIA SCHVÁLILA LIEK IMDYLLTRA® SPOLOČNOSTI AMGEN NA LIEČBU POKROČILÉHO ŠTÁDIA MALOBUNKOVÉHO KARCINÓMU PĽÚC
https://www.clinicaltrials.gov/study/NCT05740566.Rudin CM, Mountzios GS, Sun L, et al. Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small-cell lung cancer: primary analysis of Ph3 DeLLphi-304. Ústna prezentácia na: ASCO Annual Meeting;
More news about: Amgen
Jun 03, 2026, 13:35 ET EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK IMDYLLTRA® OD SPOLEČNOSTI AMGEN K LÉČBĚ EXTENZIVNÍHO STADIA MALOBUNĚČNÉHO KARCINOMU PLIC
https://www.clinicaltrials.gov/study/NCT05740566.Rudin CM, Mountzios GS, Sun L, et al. Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small-cell lung cancer: primary analysis of Ph3 DeLLphi-304. Ústní prezentace na: ASCO Annual Meeting;
More news about: Amgen
Jun 03, 2026, 13:14 ET SNEC 2026: APsystems předvádí špičková úložiště energie pro komerční a průmyslové aplikace
APstorage 241L: Efektivní, spolehlivé a hospodárné úložiště pro komerční a průmyslový sektorAPstorage 241L přináší komerčním a průmyslovým zákazníkům vynikající nákladovou efektivitu, stabilní výkon a zvýšenou
More news about: APsystems
Jun 03, 2026, 13:12 ET SNEC 2026: APsystems predstavuje špičkové riešenia pre skladovanie energie pre komerčné a priemyselné aplikácie
APstorage 241L, ktorá poskytuje výkonnú a stabilnú dlhodobú prevádzku. APstorage 241L – efektívne,
More news about: APsystems
Jun 03, 2026, 13:09 ET SNEC 2026: APsystems prezentuje wiodące w branży rozwiązania magazynowania energii dla sektora C&I
APstorage 241L - wydajne, niezawodne i ekonomiczne rozwiązanie magazynowania energii dla sektora C&IAPstorage 241L został opracowany z myślą o wysokiej efektywności kosztowej, stabilnej pracy oraz podwyższonym
More news about: APsystems
Jun 03, 2026, 13:07 ET SNEC 2026: APsystems демонстрирует ведущие в отрасли решения для накопления и хранения энергии для коммерческих и промышленных объектов
APstorage 241L, обеспечивающий мощную и стабильную долгосрочную работу. APstorage 241L — эффективное,
More news about: APsystems
Jun 03, 2026, 13:04 ET APsystems presenta soluciones líderes en la industria para el almacenamiento de energía en el sector C&I
APstorage 241L: almacenamiento eficiente, fiable y rentable para el sector C&IEl APstorage 241L ofrece una economía superior, un rendimiento estable y una mayor seguridad para aplicaciones C&I.
More news about: APsystems
Jun 03, 2026, 13:03 ET SNEC 2026: APsystems präsentiert branchenführende Energiespeicherlösungen für C&I
APstorage 241L – effizienter, zuverlässiger und kostengünstiger C&I-SpeicherDer APstorage 241L bietet überragende Wirtschaftlichkeit, stabile Leistung und verbesserte Sicherheit für Anwendungen in
More news about: APsystems
Jun 03, 2026, 13:01 ET SNEC 2026 : APsystems présente des solutions de stockage d'énergie C&I à la pointe de l'industrie
APstorage 241L - Stockage C&I efficace, fiable et rentableL'APstorage 241L offre une économie supérieure, des performances stables et une sécurité accrue pour les applications C&I. La
More news about: APsystems
Jun 03, 2026, 12:59 ET SNEC 2026: APsystems Showcases Industry-Leading C&I Energy Storage Solutions
APstorage 241L – Efficient, Reliable and Cost-Effective C&I StorageThe APstorage 241L delivers superior economy, stable performance, and enhanced safety for C&I applications. Its cabinet height
More news about: APsystems
Jun 03, 2026, 12:00 ET Neuro Launches Limited-Edition Watermelon Energy & Focus Gum for Summer
summer with the launch of its limited-edition Watermelon Energy & Focus Gum. The new flavor combines Neuro's signature blend of natural caffeine, L-theanine, B vitamins, and a juicy watermelon taste, delivering a balanced, zero-sugar boost to power summer days into evenings.
More news about: Neuro
Jun 03, 2026, 11:50 ET Last Mile Production Selects Fireblocks as Institutional Custody and Tokenization Infrastructure for LMCX Carbon Avoidance Token
deterministic data backed by physics and engineering," said Zach Wagner, CEO of Last Mile Production. "Building on a foundation that focuses on OGMP 2.0 L5 reporting means the highest accuracy and accounting of emissions. Layered on top is CAT custody and reserve management through Fireblocks, which means
More news about: CorpHQ
Jun 03, 2026, 10:34 ET THE 27TH ANNUAL BEST BUDDIES CHALLENGE: HYANNIS PORT PRESENTED BY JERSEY MIKE'S SUBS, SHAW'S AND STAR MARKET FOUNDATION AND THE TJX COMPANIES, INC. RAISES MORE THAN $4 MILLION TO SUPPORT PEOPLE WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES
ikes-subs-shaws-and-star-market-foundation-and-the-tjx-companies-inc-raises-more-than-4-million-to-support-people-with-intellectual-and-developmental--302789835.htmlSOURCE Best Buddies International
More news about: Best Buddies International
Jun 03, 2026, 10:21 ET KOMISJA EUROPEJSA ZATWIERDZA PREPARAT IMDYLLTRA® FIRMY AMGEN DO LECZENIA DROBNOKOMÓRKOWEGO RAKA PŁUCA W POSTACI ROZSIANEJ
https://www.clinicaltrials.gov/study/NCT05740566.Rudin CM, Mountzios GS, Sun L, et al. Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small-cell lung cancer: primary analysis of Ph3 DeLLphi-304 (Tarlatamab w porównaniu z chemioterapią (CTx) jako leczenie drugiego rzutu (2L) w drobnokomórkowym raku płuca: analiza pierwotna
More news about: Amgen